Mark Chin - Net Worth and Insider Trading

Mark Chin Net Worth

The estimated net worth of Mark Chin is at least $21 Million dollars as of 2024-06-05. Mark Chin is the Director of Imara Inc and owns about 2,344,072 shares of Imara Inc (IMRA) stock worth over $15 Million. Mark Chin is the Director, 10% Owner of Harpoon Therapeutics Inc and owns about 257,236 shares of Harpoon Therapeutics Inc (HARP) stock worth over $6 Million. Mark Chin is also the Director of Iterum Therapeutics PLC and owns about 72,660 shares of Iterum Therapeutics PLC (ITRM) stock worth over $108,263. Besides these, Mark Chin also holds Pyxis Oncology Inc (PYXS) . Details can be seen in Mark Chin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Chin has not made any transactions after 2022-04-21 and currently still holds the listed stock(s).

Transaction Summary of Mark Chin

To

Mark Chin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Chin owns 6 companies in total, including Iterum Therapeutics PLC (ITRM) , Harpoon Therapeutics Inc (HARP) , and Imara Inc (IMRA) among others .

Click here to see the complete history of Mark Chin’s form 4 insider trades.

Insider Ownership Summary of Mark Chin

Ticker Comapny Transaction Date Type of Owner
ITRM Iterum Therapeutics PLC 2019-05-24 director
HARP Harpoon Therapeutics Inc 2019-12-17 director & 10 percent owner
IMRA Imara Inc 2021-07-16 director & 10 percent owner
LIMIT LIMIT 2022-04-21 other: Former Director
LIMIT LIMIT 2022-12-29 director
LIMIT LIMIT 2020-03-11 director & 10 percent owner

Mark Chin Latest Holdings Summary

Mark Chin currently owns a total of 4 stocks. Among these stocks, Mark Chin owns 2,344,072 shares of Imara Inc (IMRA) as of July 16, 2021, with a value of $15 Million and a weighting of 71.08%. Mark Chin owns 257,236 shares of Harpoon Therapeutics Inc (HARP) as of December 17, 2019, with a value of $6 Million and a weighting of 28.4%. Mark Chin also owns 72,660 shares of Iterum Therapeutics PLC (ITRM) as of October 30, 2018, with a value of $108,263 and a weighting of 0.52%. The other 1 stocks Pyxis Oncology Inc (PYXS) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Mark Chin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IMRA Imara Inc 2021-07-16 2,344,072 6.32 14,814,535
HARP Harpoon Therapeutics Inc 2019-12-17 257,236 23.01 5,919,000
ITRM Iterum Therapeutics PLC 2018-10-30 72,660 1.49 108,263
PYXS Pyxis Oncology Inc 2022-04-21 0 3.65 0

Holding Weightings of Mark Chin


Mark Chin Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Chin has made a total of 2 transactions in Imara Inc (IMRA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Imara Inc is the acquisition of 1,333,333 shares on July 16, 2021, which cost Mark Chin around $8 Million.

According to the SEC Form 4 filings, Mark Chin has made a total of 2 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Harpoon Therapeutics Inc is the sale of 3,656 shares on December 17, 2019, which brought Mark Chin around $621,852.

According to the SEC Form 4 filings, Mark Chin has made a total of 0 transactions in Iterum Therapeutics PLC (ITRM) over the past 5 years. The most-recent trade in Iterum Therapeutics PLC is the acquisition of 3,867 shares on October 30, 2018, which cost Mark Chin around $353,800.

More details on Mark Chin's insider transactions can be found in the Insider Trading History of Mark Chin table.

Insider Trading History of Mark Chin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Chin Trading Performance

GuruFocus tracks the stock performance after each of Mark Chin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Chin is 9.99%. GuruFocus also compares Mark Chin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Chin within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Chin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Chin

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -8.46 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -13.85 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Chin Ownership Network

Ownership Network List of Mark Chin

No Data

Ownership Network Relation of Mark Chin

Insider Network Chart

Mark Chin Owned Company Details

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Mark Chin is the director of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Mark Chin made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Iterum Therapeutics PLC Insider Transactions

No Available Data

Mark Chin Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Chin. You might contact Mark Chin via mailing address: 20 Berkeley Square, Mayfair, London X0 W1j 6eq.

Discussions on Mark Chin

No discussions yet.